{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:36:57Z","timestamp":1782506217766,"version":"3.54.5"},"reference-count":37,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Survival in diffuse large B-cell lymphoma (DLBCL) has improved, raising interest in mortality from nonlymphoma causes in patients with DLBCL, which is known to be increased compared with the general population. We investigate excess mortality after DLBCL, quantifying both the absolute magnitude of the total nonlymphoma excess and the contributions of major disease groups. All 58\u2009221 patients aged 18 to 79 years diagnosed with DLBCL as their first lymphoma in England during 1997 to 2020 were identified and followed for up to 25 years (median, 10.2 years). Absolute excess mortality rates (AERs) and standardized mortality ratios (SMRs) were estimated. A total of 30\u2009596 patients died, 35.6% from lymphoma and 17.0% from other causes. The nonlymphoma mortality rate was 58% higher than that of the general population (SMR, 1.58; 95% confidence interval [CI], 1.55-1.61), with &amp;gt;100 excess nonlymphoma deaths per 10\u2009000 person-years (AER, 103.8; 95% CI, 98.2-109.4). The nonlymphoma AER was substantial during the first year after diagnosis (AER, 369.1; 95% CI, 349.1-389.7). It subsequently fell but remained significantly elevated throughout follow-up, even beyond 10 years (AER, 93.7; 95% CI, 80.5-107.3). Disease groups with the biggest contributions to the AER were infection &amp;lt;1 year after diagnosis, constituting 29%; hematological causes excluding lymphoma (eg, leukemia) during years 1 to 4, 38%; and solid tumors thereafter, 31% in years 5 to 9 and 34% in years 10 to 25. Deaths from circulatory disease were elevated overall, but the SMR diminished in more recent calendar years of diagnosis. These insights may help guide treatment developments, interventions, and screening strategies toward reducing excess nonlymphoma deaths in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017966","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:52:51Z","timestamp":1772657571000},"page":"3243-3254","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Causes of excess nonlymphoma death in 58\u2009000 patients with DLBCL diagnosed during 1997 to 2020 and followed for up to 25 years"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4614-629X","authenticated-orcid":false,"given":"Andrew","family":"Challenger","sequence":"first","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4112-3031","authenticated-orcid":false,"given":"Paul","family":"McGale","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-4572","authenticated-orcid":false,"given":"Jake","family":"Probert","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0767","authenticated-orcid":false,"given":"Aisling","family":"Barrett","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"},{"name":"2Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-2275","authenticated-orcid":false,"given":"John","family":"Broggio","sequence":"additional","affiliation":[{"name":"3National Disease Registration Service, NHS England, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8803-4234","authenticated-orcid":false,"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"2Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1072-6786","authenticated-orcid":false,"given":"Kavya Kayiparambil","family":"Harish","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6801-258X","authenticated-orcid":false,"given":"Lorna","family":"Roden","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-2378","authenticated-orcid":false,"given":"Daniel","family":"Royston","sequence":"additional","affiliation":[{"name":"4Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"5Department of Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6085-8449","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-0573","authenticated-orcid":false,"given":"Sarah C.","family":"Darby","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-7488","authenticated-orcid":false,"given":"David J.","family":"Cutter","sequence":"additional","affiliation":[{"name":"1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"},{"name":"2Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026051211564399000_bib1","unstructured":"Cancer Research UK Cancer Statistics for the UK. 2015. Accessed 22 December 2025. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics-for-the-uk."},{"key":"2026051211564399000_bib2","unstructured":"Haematological Malignancy Research Network Statistics. Accessed 22 December 2025. https:\/\/hmrn.org\/statistics."},{"issue":"4","key":"2026051211564399000_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2026051211564399000_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051211564399000_bib5","doi-asserted-by":"crossref","first-page":"102513","DOI":"10.1016\/j.canep.2023.102513","article-title":"Lymphoid blood cancers, incidence and survival 2005-2023: a report from the UK\u2019s haematological malignancy research network","volume":"88","author":"Lamb","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"17","key":"2026051211564399000_bib6","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.30739","article-title":"Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era","volume":"123","author":"Howlader","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"2026051211564399000_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00277-024-05619-w","article-title":"Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century","volume":"103","author":"Bei","year":"2024","journal-title":"Ann Hematol"},{"issue":"10216","key":"2026051211564399000_bib8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"The Lancet"},{"issue":"26","key":"2026051211564399000_bib9","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography\u2013directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"JCO"},{"key":"2026051211564399000_bib10","unstructured":"English indices of deprivation 2019. GOV.UK. Accessed 22 December 2025. https:\/\/www.gov.uk\/government\/statistics\/english-indices-of-deprivation-2019."},{"key":"2026051211564399000_bib11","unstructured":"National Disease Registration Service Routes to Diagnosis. Accessed 22 December 2025. https:\/\/digital.nhs.uk\/ndrs\/our-work\/ncras-work-programme\/routes-to-diagnosis."},{"key":"2026051211564399000_bib12","unstructured":"National Disease Registration Service Comorbidities and cancer. Accessed 22 December 2025. https:\/\/digital.nhs.uk\/ndrs\/our-work\/ncras-work-programme\/comorbidities-and-cancer."},{"issue":"15","key":"2026051211564399000_bib13","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"issue":"3","key":"2026051211564399000_bib14","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"issue":"4","key":"2026051211564399000_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"15","key":"2026051211564399000_bib16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.19.01937","article-title":"Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma","volume":"38","author":"Shree","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026051211564399000_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fimmu.2015.00258","article-title":"Impaired T-cell function in B-cell lymphoma: a direct consequence of events at the immunological synapse?","volume":"6","author":"Nassef Kadry Naguib Roufaiel","year":"2015","journal-title":"Front Immunol"},{"issue":"6","key":"2026051211564399000_bib18","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3390\/ijms23063368","article-title":"Effects of B-cell lymphoma on the immune system and immune recovery after treatment: the paradigm of targeted therapy","volume":"23","author":"Mancuso","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026051211564399000_bib19","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026051211564399000_bib20","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/bloodadvances.2021004286","article-title":"Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP","volume":"5","author":"Eyre","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026051211564399000_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"key":"2026051211564399000_bib22","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.blre.2020.100738","article-title":"Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL","volume":"46","author":"Ohmoto","year":"2021","journal-title":"Blood Rev"},{"key":"2026051211564399000_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2023.02.001","article-title":"Uptake of COVID-19 vaccination in people with blood cancer: population-level cohort study of 12 million patients in England","volume":"183","author":"Hirst","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026051211564399000_bib24","unstructured":"Seasonal influenza vaccine uptake in GP patients: winter season 2024 to 2025. GOV.UK. 2025. Accessed 22 December 2025. https:\/\/www.gov.uk\/government\/statistics\/seasonal-influenza-vaccine-uptake-in-gp-patients-winter-season-2024-to-2025."},{"issue":"9","key":"2026051211564399000_bib25","doi-asserted-by":"crossref","first-page":"e061699","DOI":"10.1136\/bmjopen-2022-061699","article-title":"Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database","volume":"12","author":"Du","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"2026051211564399000_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.14638","article-title":"Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era","volume":"178","author":"Tao","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2026051211564399000_bib27","doi-asserted-by":"crossref","first-page":"101035","DOI":"10.1016\/j.adro.2022.101035","article-title":"Second primary malignancies in diffuse large B-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy","volume":"7","author":"Rock","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"2026051211564399000_bib28","doi-asserted-by":"crossref","first-page":"102248","DOI":"10.1016\/j.esmoop.2024.102248","article-title":"Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma","volume":"9","author":"Geurts","year":"2024","journal-title":"ESMO Open"},{"key":"2026051211564399000_bib29","unstructured":"National Health Service Lung cancer screening. 2023. Accessed 22 December 2025. https:\/\/www.nhs.uk\/conditions\/lung-cancer-screening\/."},{"issue":"9","key":"2026051211564399000_bib30","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1002\/cam4.1572","article-title":"Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis","volume":"7","author":"Boyne","year":"2018","journal-title":"Cancer Med"},{"issue":"3","key":"2026051211564399000_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ijrobp.2009.02.045","article-title":"Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis","volume":"76","author":"Pugh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2026051211564399000_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hon.2607","article-title":"Cardiovascular mortality among patients with non-Hodgkin lymphoma: differences according to lymphoma subtype","volume":"37","author":"Abuamsha","year":"2019","journal-title":"Hematol Oncol"},{"issue":"4","key":"2026051211564399000_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jcp.55.4.275","article-title":"Death certification: an audit of practice entering the 21st century","volume":"55","author":"Swift","year":"2002","journal-title":"J Clin Pathol"},{"issue":"7","key":"2026051211564399000_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jcp.55.7.499","article-title":"Analysis of the sensitivity of death certificates in 440 hospital deaths: a comparison with necropsy findings","volume":"55","author":"Sington","year":"2002","journal-title":"J Clin Pathol"},{"issue":"6","key":"2026051211564399000_bib35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"issue":"4","key":"2026051211564399000_bib36","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(20)30031-4","article-title":"Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis","volume":"7","author":"Linschoten","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026051211564399000_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3243\/2516943\/blooda_adv-2025-017966-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3243\/2516943\/blooda_adv-2025-017966-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:56:59Z","timestamp":1778601419000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3243\/566923\/Causes-of-excess-nonlymphoma-death-in-58-000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017966","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,4]]}}}